Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study

Authors: Martina Peiskerová, Marta Kalousová, Vilem Danzig, Blanka Míková, Magdalena Hodková, Eduard Němeček, Amjad Bani-Hani, David Ambrož, Hana Benáková, Ales Linhart, Tomas Zima, Vladimir Tesař

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population.

Methods

We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2–4. Mean follow-up was 36 ±10 months. Laboratory and echocardiographic data were collected 2–3 times, at the shortest interval of 12 months apart. Multivariate regression analysis was used to detect independent correlations of variables.

Results

Increased left ventricular mass index (LVMI, g/m2.7) was found in 29% patients with CKD 2–4, left ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 30.6% patients). After 36 ± 10 months increased LVMI was found in 37.1% patients with CKD 2–4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF, cholesterol, BNP, systolic blood pressure and serum creatinine. EN-RAGE correlated positively with left atrial diameter and inversely with E/A ratio. During the follow-up we found a significant increase in LVMI and left atrial diameter, whereas a significant decrease in LVEF was noted.

Conclusion

According to our data, PlGF is independently related to increased LV mass in CKD, whereas EN-RAGE is more likely related to diastolic dysfunction in this population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Luke RG: Chronic renal failure: a vasculopathic state. N Engl J Med. 1998, 339 (12): 841-843. 10.1056/NEJM199809173391211.CrossRefPubMed Luke RG: Chronic renal failure: a vasculopathic state. N Engl J Med. 1998, 339 (12): 841-843. 10.1056/NEJM199809173391211.CrossRefPubMed
2.
go back to reference Pateinakis P, Papagianni A: Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. Int J Nephrol. 2011, 2011: 938651-CrossRefPubMedPubMedCentral Pateinakis P, Papagianni A: Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. Int J Nephrol. 2011, 2011: 938651-CrossRefPubMedPubMedCentral
3.
go back to reference Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010, 117: S10-S21.CrossRefPubMed Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010, 117: S10-S21.CrossRefPubMed
4.
go back to reference Covic A, Voroneanu L, Goldsmith D: The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?. Nephron Clin Pract. 2010, 116 (3): 187-195. 10.1159/000317198.CrossRef Covic A, Voroneanu L, Goldsmith D: The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?. Nephron Clin Pract. 2010, 116 (3): 187-195. 10.1159/000317198.CrossRef
5.
go back to reference Ogunyankin KO: Assessment of left ventricular diastolic function: the power, possibilities, and pitfalls of echocardiographic imaging techniques. Can J Cardiol. 2011, 27 (3): 311-318. 10.1016/j.cjca.2010.12.042.CrossRefPubMed Ogunyankin KO: Assessment of left ventricular diastolic function: the power, possibilities, and pitfalls of echocardiographic imaging techniques. Can J Cardiol. 2011, 27 (3): 311-318. 10.1016/j.cjca.2010.12.042.CrossRefPubMed
6.
go back to reference Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Momomura S, Ishikawa SE: Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol. 2009, 131 (2): 186-191. 10.1016/j.ijcard.2007.10.050.CrossRefPubMed Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Momomura S, Ishikawa SE: Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol. 2009, 131 (2): 186-191. 10.1016/j.ijcard.2007.10.050.CrossRefPubMed
7.
go back to reference Torry RJ, Tomanek RJ, Zheng W, Miller SJ, Labarrere CA, Torry DS: Hypoxia increases placental growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J Heart Lung Transplant. 2009, 28 (2): 183-190. 10.1016/j.healun.2008.11.917.CrossRefPubMedPubMedCentral Torry RJ, Tomanek RJ, Zheng W, Miller SJ, Labarrere CA, Torry DS: Hypoxia increases placental growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J Heart Lung Transplant. 2009, 28 (2): 183-190. 10.1016/j.healun.2008.11.917.CrossRefPubMedPubMedCentral
8.
go back to reference Pan P, Fu H, Zhang L, Huang H, Luo F, Wu W, Guo Y, Liu X: Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol. 2010, 11: 36-10.1186/1471-2121-11-36.CrossRefPubMedPubMedCentral Pan P, Fu H, Zhang L, Huang H, Luo F, Wu W, Guo Y, Liu X: Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol. 2010, 11: 36-10.1186/1471-2121-11-36.CrossRefPubMedPubMedCentral
9.
go back to reference Fialová L, Kalousová M, Soukupová J, Sulková S, Merta M, Jelínková E, Horejsí M, Srámek P, Malbohan I, Mikulíková L, Tesar V, Zima T: Relationship of pregnancy- associated plasma protein-a to renal function and dialysis modalities. Kidney Blood Press Res. 2004, 27 (2): 88-95. 10.1159/000076390.CrossRefPubMed Fialová L, Kalousová M, Soukupová J, Sulková S, Merta M, Jelínková E, Horejsí M, Srámek P, Malbohan I, Mikulíková L, Tesar V, Zima T: Relationship of pregnancy- associated plasma protein-a to renal function and dialysis modalities. Kidney Blood Press Res. 2004, 27 (2): 88-95. 10.1159/000076390.CrossRefPubMed
10.
go back to reference Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH: Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN- RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012, 220 (1): 208-214. 10.1016/j.atherosclerosis.2011.07.115.CrossRefPubMed Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH: Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN- RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012, 220 (1): 208-214. 10.1016/j.atherosclerosis.2011.07.115.CrossRefPubMed
11.
go back to reference Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W: Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant. 2011, 58 (3): 374-382. Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W: Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant. 2011, 58 (3): 374-382.
12.
go back to reference Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011, 305 (23): 2432-2439. 10.1001/jama.2011.826.CrossRefPubMedPubMedCentral Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011, 305 (23): 2432-2439. 10.1001/jama.2011.826.CrossRefPubMedPubMedCentral
13.
go back to reference Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group: Recommendations for chamber quantification: a report from the American society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr. 2005, 18 (12): 1440-1463. 10.1016/j.echo.2005.10.005.CrossRefPubMed Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group: Recommendations for chamber quantification: a report from the American society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr. 2005, 18 (12): 1440-1463. 10.1016/j.echo.2005.10.005.CrossRefPubMed
14.
go back to reference Chao TF, Wang KL, Chuang CF, Chen SA, Yu WC: Atrium electromechanical interval in left ventricular diastolic dysfunction. Eur J Clin Invest. 2011, 42 (2): 117-122.CrossRefPubMed Chao TF, Wang KL, Chuang CF, Chen SA, Yu WC: Atrium electromechanical interval in left ventricular diastolic dysfunction. Eur J Clin Invest. 2011, 42 (2): 117-122.CrossRefPubMed
15.
go back to reference Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009, 10 (2): 165-193.CrossRefPubMed Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009, 10 (2): 165-193.CrossRefPubMed
16.
go back to reference Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005, 46 (5): 799-811. 10.1053/j.ajkd.2005.08.007.CrossRefPubMed Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005, 46 (5): 799-811. 10.1053/j.ajkd.2005.08.007.CrossRefPubMed
17.
go back to reference Cioffi G, Tarantini L, Frizzi R, Stefenelli C, Russo TE, Selmi A, Toller C, Furlanello F, de Simone G: Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. J Hypertens. 2011, 29 (3): 565-573. 10.1097/HJH.0b013e3283424188.CrossRefPubMed Cioffi G, Tarantini L, Frizzi R, Stefenelli C, Russo TE, Selmi A, Toller C, Furlanello F, de Simone G: Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. J Hypertens. 2011, 29 (3): 565-573. 10.1097/HJH.0b013e3283424188.CrossRefPubMed
18.
go back to reference Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G: Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?. Nephrol Dial Transplant. 2011, 26 (2): 670-677. 10.1093/ndt/gfq409.CrossRefPubMed Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G: Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?. Nephrol Dial Transplant. 2011, 26 (2): 670-677. 10.1093/ndt/gfq409.CrossRefPubMed
19.
go back to reference Soleimani A, Nasiri O, Nikoueinejad H, Yousefzade M, Foroozanfard F, Tabatabaizadeh M, Moraveji SA, Rajali M: Prognostic value of B-type natriuretic peptide for assessment of left ventricular function in patients with chronic kidney disease. Iran J Kidney Dis. 2011, 5 (4): 242-247.PubMed Soleimani A, Nasiri O, Nikoueinejad H, Yousefzade M, Foroozanfard F, Tabatabaizadeh M, Moraveji SA, Rajali M: Prognostic value of B-type natriuretic peptide for assessment of left ventricular function in patients with chronic kidney disease. Iran J Kidney Dis. 2011, 5 (4): 242-247.PubMed
20.
go back to reference Henkel DM, Glockner J, Miller WL: Association of myocardial fibrosis, B-type natriuretic peptide, and cardiac magnetic resonance parameters of remodeling in chronic ischemic cardiomyopathy. Am J Cardiol. 2011, 109 (3): 390-394.CrossRefPubMed Henkel DM, Glockner J, Miller WL: Association of myocardial fibrosis, B-type natriuretic peptide, and cardiac magnetic resonance parameters of remodeling in chronic ischemic cardiomyopathy. Am J Cardiol. 2011, 109 (3): 390-394.CrossRefPubMed
21.
go back to reference Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010, 5 (5): 805-813. 10.2215/CJN.07761109.CrossRefPubMedPubMedCentral Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010, 5 (5): 805-813. 10.2215/CJN.07761109.CrossRefPubMedPubMedCentral
22.
go back to reference Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD: Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol. 2011, 33 (2): 139-149. 10.1159/000323551.CrossRefPubMed Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD: Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol. 2011, 33 (2): 139-149. 10.1159/000323551.CrossRefPubMed
23.
go back to reference Accornero F, van Berlo JH, Benard MJ, Lorenz JN, Carmeliet P, Molkentin JD: Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res. 2011, 109 (3): 272-280. 10.1161/CIRCRESAHA.111.240820.CrossRefPubMed Accornero F, van Berlo JH, Benard MJ, Lorenz JN, Carmeliet P, Molkentin JD: Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res. 2011, 109 (3): 272-280. 10.1161/CIRCRESAHA.111.240820.CrossRefPubMed
24.
go back to reference Roncal C, Buysschaert I, Gerdes N, Georgiadou M, Ovchinnikova O, Fischer C, Stassen JM, Moons L, Collen D, De Bock K, Hansson GK, Carmeliet P: Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res. 2010, 86 (1): 29-36. 10.1093/cvr/cvp380.CrossRefPubMed Roncal C, Buysschaert I, Gerdes N, Georgiadou M, Ovchinnikova O, Fischer C, Stassen JM, Moons L, Collen D, De Bock K, Hansson GK, Carmeliet P: Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res. 2010, 86 (1): 29-36. 10.1093/cvr/cvp380.CrossRefPubMed
25.
go back to reference Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC: Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005, 111 (21): 2828-2836. 10.1161/CIRCULATIONAHA.104.495887.CrossRefPubMed Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC: Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005, 111 (21): 2828-2836. 10.1161/CIRCULATIONAHA.104.495887.CrossRefPubMed
26.
go back to reference Cassidy A: Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol. 2009, 29 (1): 134-139. 10.1161/ATVBAHA.108.171066.CrossRefPubMed Cassidy A: Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol. 2009, 29 (1): 134-139. 10.1161/ATVBAHA.108.171066.CrossRefPubMed
27.
go back to reference Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME: Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010, 120 (11): 3891-3900. 10.1172/JCI40205.CrossRefPubMedPubMedCentral Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME: Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010, 120 (11): 3891-3900. 10.1172/JCI40205.CrossRefPubMedPubMedCentral
28.
go back to reference Zakiyanov O, Kalousová M, Zima T, Tesař V: Placental growth factor in patients with decreased renal function. Ren Fail. 2011, 33 (3): 291-297. 10.3109/0886022X.2011.560402.CrossRefPubMed Zakiyanov O, Kalousová M, Zima T, Tesař V: Placental growth factor in patients with decreased renal function. Ren Fail. 2011, 33 (3): 291-297. 10.3109/0886022X.2011.560402.CrossRefPubMed
29.
go back to reference McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG: Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant. 2011, 26 (3): 933-938. 10.1093/ndt/gfq418.CrossRefPubMed McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG: Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant. 2011, 26 (3): 933-938. 10.1093/ndt/gfq418.CrossRefPubMed
30.
go back to reference Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB: Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif. 2011, 31 (1–3): 26-32.CrossRefPubMed Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB: Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif. 2011, 31 (1–3): 26-32.CrossRefPubMed
31.
go back to reference Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121 (11): 4393-4408. 10.1172/JCI46122.CrossRefPubMedPubMedCentral Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121 (11): 4393-4408. 10.1172/JCI46122.CrossRefPubMedPubMedCentral
32.
go back to reference Patel RK, Jardine AG, Mark PB, Cunningham AF, Steedman T, Powell JR, McQuarrie EP, Stevens KK, Dargie HJ, Jardine AG: Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation. Am J Kidney Dis. 2010, 55 (6): 1088-1096. 10.1053/j.ajkd.2009.12.033.CrossRefPubMedPubMedCentral Patel RK, Jardine AG, Mark PB, Cunningham AF, Steedman T, Powell JR, McQuarrie EP, Stevens KK, Dargie HJ, Jardine AG: Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation. Am J Kidney Dis. 2010, 55 (6): 1088-1096. 10.1053/j.ajkd.2009.12.033.CrossRefPubMedPubMedCentral
33.
go back to reference Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V: Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant. 2012, 27 (4): 1437-1445. 10.1093/ndt/gfr447.CrossRefPubMed Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V: Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant. 2012, 27 (4): 1437-1445. 10.1093/ndt/gfr447.CrossRefPubMed
34.
go back to reference Chen SC, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC: Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant. 2012, 27 (3): 1064-1070. 10.1093/ndt/gfr407.CrossRefPubMed Chen SC, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC: Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant. 2012, 27 (3): 1064-1070. 10.1093/ndt/gfr407.CrossRefPubMed
35.
go back to reference Hung MJ, Yang NI, Wu IW, Cheng CW, Liu PC, Chen SJ, Wu MS, Cherng WJ: Three-dimensional echocardiographic assessment of left ventricular remodeling in predialysis chronic kidney disease patients. J Nephrol. 2011, 25 (1): 96-106.CrossRef Hung MJ, Yang NI, Wu IW, Cheng CW, Liu PC, Chen SJ, Wu MS, Cherng WJ: Three-dimensional echocardiographic assessment of left ventricular remodeling in predialysis chronic kidney disease patients. J Nephrol. 2011, 25 (1): 96-106.CrossRef
36.
go back to reference Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA: Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol. 2011, 33 (3): 250-259. 10.1159/000324693.CrossRefPubMedPubMedCentral Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA: Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol. 2011, 33 (3): 250-259. 10.1159/000324693.CrossRefPubMedPubMedCentral
37.
go back to reference Mahajan N, Bahl A, Dhawan V: C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol. 2010, 142 (3): 273-278. 10.1016/j.ijcard.2009.01.008.CrossRefPubMed Mahajan N, Bahl A, Dhawan V: C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol. 2010, 142 (3): 273-278. 10.1016/j.ijcard.2009.01.008.CrossRefPubMed
38.
go back to reference Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C: Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2012, 22 (9): 748-755. 10.1016/j.numecd.2010.11.008.CrossRefPubMed Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C: Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2012, 22 (9): 748-755. 10.1016/j.numecd.2010.11.008.CrossRefPubMed
39.
go back to reference Lindsey JB, Cipollone F, Abdullah SM, McGuire DK: Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009, 6 (1): 7-14. 10.3132/dvdr.2009.002.CrossRefPubMed Lindsey JB, Cipollone F, Abdullah SM, McGuire DK: Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009, 6 (1): 7-14. 10.3132/dvdr.2009.002.CrossRefPubMed
40.
go back to reference Zamboli P, De Nicola L, Minutolo R, Chiodini P, Crivaro M, Tassinario S, Bellizzi V, Conte G: Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant. 2011, 26 (5): 1575-1583. 10.1093/ndt/gfq565.CrossRefPubMed Zamboli P, De Nicola L, Minutolo R, Chiodini P, Crivaro M, Tassinario S, Bellizzi V, Conte G: Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant. 2011, 26 (5): 1575-1583. 10.1093/ndt/gfq565.CrossRefPubMed
41.
go back to reference Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012, 307 (7): 674-684. 10.1001/jama.2012.120.CrossRefPubMed Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012, 307 (7): 674-684. 10.1001/jama.2012.120.CrossRefPubMed
42.
go back to reference Metz CE: Basic principles of ROC analysis. Semin Nucl Med. 1978, 8 (4): 283-298. 10.1016/S0001-2998(78)80014-2.CrossRefPubMed Metz CE: Basic principles of ROC analysis. Semin Nucl Med. 1978, 8 (4): 283-298. 10.1016/S0001-2998(78)80014-2.CrossRefPubMed
Metadata
Title
Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study
Authors
Martina Peiskerová
Marta Kalousová
Vilem Danzig
Blanka Míková
Magdalena Hodková
Eduard Němeček
Amjad Bani-Hani
David Ambrož
Hana Benáková
Ales Linhart
Tomas Zima
Vladimir Tesař
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-142

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.